



Universiteit  
Leiden  
The Netherlands

## Targeting HLA class II in allogeneic stem cell transplantation

Balen, P. van

### Citation

Balen, P. van. (2021, October 27). *Targeting HLA class II in allogeneic stem cell transplantation*. Retrieved from <https://hdl.handle.net/1887/3221294>

Version: Publisher's Version

License: [Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden](#)

Downloaded from: <https://hdl.handle.net/1887/3221294>

**Note:** To cite this publication please use the final published version (if applicable).



# CHAPTER 1

General introduction

## ALLOGENEIC STEM CELL TRANSPLANTATION

Allogeneic stem cell transplantation (alloSCT) provides a potentially curative therapy for patients with a variety of hematologic malignancies. Besides the therapeutic effect of the pre-transplant condition regimen with chemotherapy or radiation therapy, the most important therapeutic effect of alloSCT is due to an immune response of donor immune cells against the malignancy of the patient. In alloSCT not only stem cells of the donor are transfused into the patient, but also donor T cells. The aim is that these donor T cells induce an immune response against patient hematopoietic cells. Since the malignancy the patient is treated for, is a malignancy of hematopoietic origin, an immune response against patient hematopoiesis is an immune response against the disease of the patient. The immune response of donor T cells directed against the malignant hematopoietic cells, which usually include an immune response to other hematopoietic cells of the patient, is called graft-versus-leukemia (GVL) reactivity. However, donor T cells can also be directed against non-hematopoietic healthy tissues of the patient, causing graft-versus-host disease (GVHD). GVHD and treatment of GVHD with immunosuppressive agents remain major causes of transplant related morbidity and mortality. The ultimate aim in treatment with alloSCT is to find the optimal balance between the beneficial GVL reactivity and the detrimental GVHD. The most efficient method to prevent GVHD is T-cell depletion (TCD) of the graft. AlloSCT regimens using infusion of positively selected CD34 cells, grafts depleted of alpha-beta T cells or CD3 T cells, or using the CD52 antibody Alemtuzumab for TCD have demonstrated efficient engraftment and reduced acute GVHD.<sup>1-10</sup> However, TCD substantially impairs post-transplant anti-viral and anti-tumor immunity.<sup>4,11,12</sup> Due to the reduced antitumor effect of TCD grafts, post-transplant donor lymphocyte infusion (DLI) containing donor T cells, may be needed for treatment persistent disease or for minimizing the relapse risk by eliminating residual patient hematopoiesis after alloSCT. TCD alloSCT with postponed DLI is indeed associated with GVL reactivity and with reduced incidence of GVHD.<sup>4,13-17</sup> Since the ultimate aim in alloSCT is to induce GVL without GVHD, it is important to explore whether the postponed DLI can be manipulated to better achieve this goal.

## ANTIGEN PRESENTATION ON CELL SURFACE AND RECOGNITION BY T CELLS

Under normal circumstances in a healthy individual, T cells can detect the presence of pathogens because infected cells display peptide fragments derived from pathogen specific proteins on their surface. These foreign peptides are presented to T cells by major histocompatibility complex (MHC) molecules, also called human leucocyte antigen (HLA) molecules. There are two classes of these highly polymorphic HLA molecules, HLA class I and HLA class II. Both molecules consists of two domains that fold together to create a cleft or binding groove, where the peptide binds to the HLA molecule. Peptides presented in HLA class I molecules can be recognized by CD8 T cells and after recognition these CD8 T cells can exert direct cytotoxicity towards the target cell presenting the peptide. Peptides presented in HLA class II can be recognized by CD4 T cells and after recognition these CD4

T cells can exert direct cytotoxicity on target cells, can provide help to the development and persistence of CD8 T-cell responses or can activate macrophages or B cells to help fighting the pathogen. Under normal circumstances, T cells will only recognize foreign peptides presented in self-HLA molecules of an individual. Due to positive and negative thymic selection, T cells are able to recognize a multitude of foreign molecules without attacking the body itself. Positive selection involves the selection of developing T cells that can recognize self-HLA molecules expressed in the thymus. Negative selection prevents the survival of T cells that interact with self-peptides presented in the thymus. The result is that only T cells recognizing non-self-peptides in self-HLA remain present.

The presentation of peptides by HLA molecules is the result of a series of reactions that are different between HLA class I and class II molecules. For presentation in HLA class I, proteins are degraded by the proteasome and the resulting peptides are translocated via transporter associated with antigen presentation (TAP) into the endoplasmic reticulum (ER) lumen and loaded onto HLA class I molecules. Peptide–HLA class I complexes are released from the ER and transported via the Golgi apparatus to the plasma membrane for antigen presentation to CD8 T cells.<sup>18</sup> The process of peptide presentation in HLA class II is different. HLA class II  $\alpha$ - and  $\beta$ -chains assemble in the ER and form a complex with the invariant chain (Ii). The Ii–HLA class II heterotrimer is transported through the Golgi apparatus to the HLA class II compartment. Endocytosed proteins and Ii are degraded by resident proteases in this compartment. The HLA class II associated Ii peptide (CLIP) fragment of Ii remains in the peptide-binding groove of the HLA class II dimer and is exchanged for an antigenic peptide with the help of the dedicated chaperone HLA-DM. HLA class II molecules are then transported to the plasma membrane to present antigenic peptides to CD4 T cells.<sup>18</sup> HLA-DO is another molecule playing a role in peptide presentation in HLA class II. HLA-DO is an HLA class II mimic and functions as a competitive and essentially irreversible inhibitor of HLA-DM activity.<sup>19</sup> Presence of HLA-DO in a cell expands the repertoire of peptides presented by HLA class II molecules.<sup>20,21</sup> HLA-DO is mainly expressed in hematopoietic cells, especially B cells, and not in non-hematopoietic cells.<sup>22</sup> Therefore, it is possible that some particular peptides are only presented if HLA-DM activity is inhibited by the presence of HLA-DO.

HLA molecules present either peptides derived from pathogens or peptides derived from self-proteins. In the setting of alloSCT donor T cells will recognize patient derived peptides as foreign and attack patient cells if the presented peptide is polymorphic and different between patient and donor. The recognized cell is targeted because of the presence of a foreign peptide in HLA and depending on which cells the peptide is presented, different tissues will be attacked. If the recognized peptide is expressed on hematopoietic cells, including the malignant hematopoietic cells of the patient, GVH will be the result. However, if the recognized peptide is expressed in normal tissues other than hematopoietic tissue, GVHD will occur.

## EXPRESSION OF HLA CLASS I AND II MOLECULES

HLA class I molecules are expressed on all nucleated human cells.<sup>18</sup> In contrast to HLA class I, constitutive expression of HLA class II molecules is predominantly restricted to normal and malignant hematopoietic cells.<sup>23-26</sup> This hematopoiesis restricted expression makes targeting of HLA class II molecules by donor alloreactive CD4 T cells interesting in the setting of alloSCT, where an hematopoiesis restricted immune response is aimed for. This is one of the reasons that in the Leiden University Medical Center a clinical trial was started in which patients are being treated with purified donor CD4 T cells three months after TCD alloSCT. Besides the primary endpoint of immune reconstitution, conversion of mixed chimerism after alloSCT due to infusion of donor CD4 T cells is being investigated as secondary endpoint. Since CD4 T cells target peptides in HLA class II and HLA class II under non-inflammatory circumstances is predominantly expressed on hematopoietic cells, including malignant hematopoietic cells, GVL without GVHD could be the result of infusion of donor CD4 T cells. Previously it has been demonstrated that GVL reactivity can indeed be caused by donor CD4 T cells recognizing peptides presented in HLA class II.<sup>27,28</sup> However, the period after alloSCT is often complicated by inflammatory conditions in the patient and it is known that expression of HLA class II molecule can be upregulated under inflammatory conditions like CMV reactivations.<sup>18,29</sup> The result of this upregulation of HLA class II on non-hematopoietic cells makes GVHD target tissues vulnerable for recognition after infusion of CD4 donor T cells. Therefore, under specific clinical circumstances, both GVL and GVHD can be expected after CD4 T cell infusion after alloSCT.

## TARGETING MINOR HISTOCOMPATIBILITY ANTIGENS PRESENTED IN HLA CLASS II

The immune response of donor T cells directed against patients cells is based on recognition of a non-self-peptide-HLA complex in the recipient. This complex can be non-self due to a non-self-peptide, to a non-self HLA molecule or both. Searching for a suitable alloSCT donor starts with identifying potential HLA identical siblings. In the setting of an HLA identical transplantation, the immune response of donor T cells will be directed to a non-self-peptide presented in self HLA since all HLA alleles are shared between donor and recipient. The non-self-peptides that can be recognized by alloreactive donor T cells are called minor histocompatibility antigens (MiHA). MiHA are polymorphic peptides derived from genes containing genetic differences between patient and donor. These polymorphic peptides can be encoded by the male-specific Y-chromosome (H-Y antigens) or other chromosomes (autosomal MiHA). The molecular mechanisms by which genetic variants can create autosomal MiHA include several ways. First, MiHA can be created by single nucleotide polymorphisms (SNP) between donor and recipient in primary gene transcripts in the normal or an alternative reading frame. Second, MiHA that are derived from polymorphic proteins as created by frameshift insertions or deletions in primary gene transcripts. And third, MiHA that are encoded by polymorphic genes (gene deletion).<sup>30</sup> All these molecular mechanisms can result in the presentation of a recipient derived peptide

that is foreign to donor T cells.

Following HLA identical alloSCT, infusion of donor CD8 T cells recognizing HLA class I restricted MiHA that are expressed on all nucleated cells can result in GVL and GVHD. Donor CD8 T cells recognizing MiHA selectively expressed in hematopoietic cells may result in destruction of patient hematopoietic cells including the malignant cells, without harming other normal tissues.<sup>30-35</sup> Since HLA class II is predominantly expressed on hematopoietic cells only, donor CD4 T cells recognizing HLA class II restricted MiHA may result in selective recognition of recipient normal and malignant hematopoietic cells, thereby inducing GVL without GVHD, even if MiHA are targeted that are encoded by genes that are broadly expressed in recipient tissues.<sup>36-40</sup> However, under inflammatory circumstances, expression of HLA class II is significantly upregulated on non-hematopoietic cells, making these tissues susceptible to recognition by CD4 T cells. It was previously demonstrated that, unlike presentation of MiHA in HLA class I, not all MiHA encoded by broadly expressed genes are adequately presented in HLA class II on non-hematopoietic cells due to differences in peptide processing between different cell types, based on presence or absence of HLA-DO.<sup>20</sup> Thus, even under inflammatory conditions, GVHD target tissues may not always be damaged by CD4 T cells recognizing MiHA encoded by broadly expressed genes. This combination of relatively hematopoiesis restricted expression of HLA class II molecules and limited presentation of several broadly expressed MiHA in HLA class II, makes infusion of donor CD4 T cells after alloSCT an attractive strategy to separate GVL from GVHD.

### **HLA MATCHING BETWEEN PATIENT AND DONOR**

HLA molecules are highly polymorphic. Probably the presence of many different HLA molecules makes it possible to present many different peptides from pathogens and thereby protecting a population against being eliminated by infectious diseases.<sup>41</sup>

One of the factors that influences the balance between GVL and GVHD after alloSCT is the degree of HLA matching between patient and donor. In case more HLA alleles are mismatched, the risk of developing GVHD is higher.<sup>42-45</sup> The reason is that mismatched HLA molecules can be targets for immune responses by donor T cells after alloSCT.<sup>46</sup> The T-cell repertoire of a healthy individual contains T cells interacting with peptides in the context of non-self-HLA molecules. Mixed lymphocyte reactions showed that roughly 1-10% of all T cells in an individual may respond to stimulation by cells from allogeneic HLA mismatched individuals.<sup>47-50</sup> The frequency of these T cells recognizing mismatched HLA molecules is much higher than the precursor frequency of known MiHA specific T cells recognizing the MiHA in self-HLA.<sup>30</sup> Therefore, an HLA mismatch between patient and donor is more likely to induce an immune response by donor T cells and the risk of developing GVHD will be higher. The high frequencies of allo-HLA reactive T cells is the reason for preferring HLA matched donors. If an HLA identical sibling donor is not available, a matched unrelated

donor (MUD) is searched. Mainly the HLA loci classified as high expression loci (HEL) HLA-A, B, C and DRB1 are taken into account in the donor selection, since mismatches in HLA-HEL are strongly associated with an increased incidence of severe GVHD.<sup>44,51,52</sup> If patient and donor are matched for these HLA alleles, it is called an 8/8 HLA match. In contrast, HLA-DRB3, 4 and 5, HLA-DQ and HLA-DP are usually assumed to be low expression loci (LEL) based on their surface expression.<sup>53,54</sup> HLA-LEL mismatches were considered not to be associated with adverse outcome in HLA 8/8 matched alloSCT and therefore are frequently not taken into account in donor selection.<sup>53</sup> However, it has been demonstrated that immune responses against mismatched HLA-DQ can contribute to the development of both GVHD and GVL reactivity.<sup>42,55,56</sup> Therefore, in many centers a matched unrelated donor is searched for that is HLA 10/10 matched, meaning matched for HLA-A, B, C, DRB1 and DQB1. In the setting of HLA 10/10 matched transplantations, besides potential GVL and GVHD due to recognition of MiHA in a shared HLA molecule, there is additional potential GVL and GVHD due to recognition of allo-HLA molecules by donor T cells, since the HLA class II alleles HLA-DRB3, -DRB4, -DRB5 and -DPB1 can be mismatched. After infusion of CD4 donor T cells, also these alleles can be targeted.

#### **HLA-DP MISMATCHES IN alloSCT**

Unrelated donors for alloSCT who are HLA 10/10 matched with the recipient are mismatched for HLA-DP in 71-88% of cases.<sup>57-60</sup> Although not taken into account in donor selection, immune responses by donor CD4 T cells against this mismatched HLA allele can result in both GVL and GVHD.<sup>27,29,61</sup> Not all mismatches in HLA-DP between donor and patient turned out to be equally immunogenic. HLA-DPB1 alleles have been categorized into T-cell epitope (TCE) groups based on in vitro experiments using recognition patterns of anti-HLA-DP directed T cells and amino acid sequences of the binding groove defining functional distance among the different HLA-DPB1 alleles.<sup>62-64</sup> Based on this classification, HLA-DP mismatches have been classified as permissive (mismatch within the same TCE group) or non-permissive (mismatch across different TCE groups) with predictive value for the outcome of transplantation.<sup>62,65-68</sup> Others conclude that the difference in immunogenicity of HLA-DP mismatches is based on differences in expression of HLA-DP alleles due to the absence or presence of SNP rs9277534.<sup>69</sup> It has been shown that polymorphisms within the peptide binding groove of HLA-DP molecules are more important for HLA-DP restricted alloreactivity than polymorphisms outside the peptide binding groove.<sup>63,70</sup> Therefore, it is possible that differences in composition of peptides bound to the various HLA-DP molecules determine the potency to induce immune responses between mismatched HLA-DP molecules. Mismatched HLA-DP alleles that are more similar to each other and present similar peptides will then be more permissive than mismatched HLA-DP alleles with large structural differences presenting different peptides.



## AIM OF THIS STUDY

Donor CD4 T cell infusion may be an attractive strategy for separating GVL and GVHD because of the relatively hematopoiesis restricted expression of HLA class II molecules. Therefore, the aim of this thesis is to investigate in detail the immunological effects of donor CD4 T cell infusion after TCD alloSCT and to explore whether this strategy indeed can separate GVL from GVHD.

Since CD4 T cells target HLA class II expressing cells, the first aim is to answer the question which patient derived cells express HLA class II after alloSCT. HLA class II expression is upregulated under inflammatory conditions. Thus tissue damage caused by the conditioning regimen before alloSCT may influence the expression of HLA class II alleles on GVHD target tissue.

In **chapter 2** the hypothesis was investigated that activated patient originated HLA class II positive cells are present for several months in skin due to tissue damage caused by the conditioning regimen given before alloSCT and that these HLA class II positive cells are able to initiate an immune response by donor T cells. To investigate this, the quantitative presence of HLA class II expressing cells and T cells in the dermal layer was substantiated by dermal area count calculation in skin biopsies taken from patients at several time points from transplantation, and compared to normal skin biopsies. To investigate whether the HLA class II positive cells and T cells were of patient or donor origin, XY-FISH combined with staining of HLA class II was performed after alloSCT from patients with a gender mismatched donor.

The second aim of this thesis is to investigate whether donor CD4 T cells from HLA matched sibling donors can induce GVL without GVHD after alloSCT by targeting HLA class II restricted MiHA. In **chapter 3** we investigated in detail the observed hematopoiesis restricted immune responses after CD4 DLI, as illustrated by conversion from mixed to full donor chimerism, without GVHD in four patients transplanted with an HLA identical sibling donor. Alloreactive CD4 T cells were isolated from blood and bone marrow after CD4 DLI and using whole genome association scanning, the MiHA that were recognized by alloreactive CD4 T cells were identified. Some of the identified MiHA turned out to be encoded by genes with broad expression in both hematopoietic cells as well as non-hematopoietic cells. Since an hematopoietic restricted immune response was observed in patients, we aimed to identify factors responsible for this hematopoietic restricted immune response besides hematopoiesis restricted expression of HLA class II. We investigated whether differences in peptide processing between hematopoietic and non-hematopoietic cells in the presence or absence of HLA-DO was of influence in separating GVL from GVHD.

Donor CD4 T cells can target the HLA class II molecules HLA-DQ and HLA-DP in case of a mismatch in these alleles between patient and donor. However, also the HLA class II molecules HLA-DRB3, -DRB4 and -DRB5 can be mismatched between patient and donor in case of an HLA 10/10 MUD. These HLA-LEL are not taken into account in donor selection since they are regarded as not relevant in alloSCT. We aimed to investigate whether donor CD4 T cells from HLA 10/10 MUD can induce an immune response targeting mismatched HLA-DRB3. In **chapter 4**, we analysed the immune response in a patient who received purified CD4 donor lymphocytes 3 months after TCD alloSCT. Afterwards conversion from mixed to full donor chimerism occurred in the presence of skin and liver GVHD. Patient and donor were HLA 10/10 matched, but mismatched for HLA-DRB3 and HLA-DPB1. We investigated whether these mismatched HLA-LEL class II molecules were the target of recognition and whether CD4 T cells targeting mismatched HLA class II molecule are likely to have caused the immune response consisting of GVL and GVHD.

In the setting of alloSCT with HLA 10/10 matched, but HLA-DP mismatched donors, some HLA-DP mismatches are more permissive and less immunogenic than other mismatches. HLA-DPB1 alleles have been categorized into TCE groups and based on this classification, HLA-DP mismatches have been classified as permissive (mismatch within the same TCE group) or non-permissive (mismatch across different TCE groups) with predictive value for the outcome of transplantation. The functional groups of TCE-1 alleles (HLA-DPB1\*09:01, 10:01 and 17:01) and TCE-2 alleles (HLA-DPB1\*03:01, 14:01 and 45:01) were clearly defined, but TCE-3 included any HLA-DPB1 allele not belonging to either group 1 or 2, and represents a relatively heterogeneous group. In **chapter 5**, we aimed to redefine the current classification into TCE groups and to unravel potential new functional hierarchies of different HLA-DP mismatches in the setting of alloSCT. The hypothesis was that HLA-DP molecules that are structurally more similar to each other and present more similar peptides, are less immunogenic when mismatched and that HLA-DP molecules that are structurally more different and present more different peptides are more immunogenic when mismatched. To investigate whether permissiveness and non-permissiveness with respect to alloreactivity in the context of alloSCT could be defined based on the similarity or differences in their respective immunopeptidomes, we analysed the peptidome of the 12 common HLA-DP molecules.

In **chapter 6** the most important results of the performed analyses are summarized and the relevance of the results in the light of the current knowledge are discussed.

## REFERENCES

1. Pasquini MC, Devine S, Mendizabal A, et al. Comparative outcomes of donor graft CD34+ selection and immune suppressive therapy as graft-versus-host disease prophylaxis for patients with acute myeloid leukemia in complete remission undergoing HLA-matched sibling allogeneic hematopoietic cell transplantation. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*. 2012;30(26):3194-3201.
2. Bayraktar UD, de Lima M, Saliba RM, et al. Ex vivo T cell-depleted versus unmodified allografts in patients with acute myeloid leukemia in first complete remission. *Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation*. 2013;19(6):898-903.
3. Kottaridis PD, Milligan DW, Chopra R, et al. In vivo CAMPATH-1H prevents graft-versus-host disease following nonmyeloablative stem cell transplantation. *Blood*. 2000;96(7):2419-2425.
4. Barge RM, Starrenburg CW, Falkenburg JH, Fibbe WE, Marijt EW, Willemze R. Long-term follow-up of myeloablative allogeneic stem cell transplantation using Campath "in the bag" as T-cell depletion: the Leiden experience. *Bone marrow transplantation*. 2006;37(12):1129-1134.
5. Maschan M, Shelikhova L, Ilushina M, et al. TCR-alpha/beta and CD19 depletion and treosulfan-based conditioning regimen in unrelated and haploidentical transplantation in children with acute myeloid leukemia. *Bone marrow transplantation*. 2016;51(5):668-674.
6. Balashov D, Shcherbina A, Maschan M, et al. Single-Center Experience of Unrelated and Haploidentical Stem Cell Transplantation with TCRAlphabeta and CD19 Depletion in Children with Primary Immunodeficiency Syndromes. *Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation*. 2015;21(11):1955-1962.
7. Locatelli F, Merli P, Pagliara D, et al. Outcome of children with acute leukemia given HLA-haploidentical HSCT after alphabeta T-cell and B-cell depletion. *Blood*. 2017;130(5):677-685.
8. Bertaina A, Merli P, Rutella S, et al. HLA-haploidentical stem cell transplantation after removal of alphabeta+ T and B cells in children with nonmalignant disorders. *Blood*. 2014;124(5):822-826.
9. Seif AE, Li Y, Monos DS, et al. Partially CD3(+)-Depleted Unrelated and Haploidentical Donor Peripheral Stem Cell Transplantation Has Favorable Graft-versus-Host Disease and Survival Rates in Pediatric Hematologic Malignancy. *Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation*. 2020;26(3):493-501.
10. Oved JH, Wang Y, Barrett DM, et al. CD3(+)/CD19(+) Depleted Matched and Mismatched Unrelated Donor Hematopoietic Stem Cell Transplant with Targeted T Cell Addback Is Associated with Excellent Outcomes in Pediatric Patients with Nonmalignant Hematologic Disorders. *Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation*. 2019;25(3):549-555.
11. Chakrabarti S, Mackinnon S, Chopra R, et al. High incidence of cytomegalovirus infection after nonmyeloablative stem cell transplantation: potential role of Campath-1H in delaying immune reconstitution. *Blood*. 2002;99(12):4357-4363.
12. Chakrabarti S, Mautner V, Osman H, et al. Adenovirus infections following allogeneic stem cell transplantation: incidence and outcome in relation to graft manipulation, immunosuppression, and immune recovery. *Blood*. 2002;100(5):1619-1627.
13. Collins RH, Jr., Shpilberg O, Drobyski WR, et al. Donor leukocyte infusions in 140 patients with relapsed

- malignancy after allogeneic bone marrow transplantation. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*. 1997;15(2):433-444.
14. Peggs KS, Thomson K, Hart DP, et al. Dose-escalated donor lymphocyte infusions following reduced intensity transplantation: toxicity, chimerism, and disease responses. *Blood*. 2004;103(4):1548-1556.
  15. Eefting M, Halkes CJ, de Wreede LC, et al. Myeloablative T cell-depleted alloSCT with early sequential prophylactic donor lymphocyte infusion is an efficient and safe post-remission treatment for adult ALL. *Bone marrow transplantation*. 2014;49(2):287-291.
  16. Eefting M, de Wreede LC, Halkes CJ, et al. Multi-state analysis illustrates treatment success after stem cell transplantation for acute myeloid leukemia followed by donor lymphocyte infusion. *Haematologica*. 2016;101(4):506-514.
  17. Eefting M, von dem Borne PA, de Wreede LC, et al. Intentional donor lymphocyte-induced limited acute graft-versus-host disease is essential for long-term survival of relapsed acute myeloid leukemia after allogeneic stem cell transplantation. *Haematologica*. 2014;99(4):751-758.
  18. Neeffjes J, Jongsma ML, Paul P, Bakke O. Towards a systems understanding of MHC class I and MHC class II antigen presentation. *Nature reviews Immunology*. 2011;11(12):823-836.
  19. Guce AI, Mortimer SE, Yoon T, et al. HLA-DO acts as a substrate mimic to inhibit HLA-DM by a competitive mechanism. *Nat Struct Mol Biol*. 2013;20(1):90-98.
  20. Kremer AN, van der Meijden ED, Honders MW, et al. Endogenous HLA class II epitopes that are immunogenic in vivo show distinct behavior toward HLA-DM and its natural inhibitor HLA-DO. *Blood*. 2012;120(16):3246-3255.
  21. Warren EH. Diversifying the MHC peptide portfolio. *Blood*. 2012;120(16):3165-3167.
  22. van Ham M, van Lith M, Griekspoor A, Neeffjes J. What to do with HLA-DO? *Immunogenetics*. 2000;51(10):765-770.
  23. Aglietta M, Piacibello W, Stacchini A, et al. Expression of HLA class II (DR, DQ) determinants by normal and chronic myeloid leukemia granulocyte/monocyte progenitors. *Cancer Res*. 1986;46(4 Pt 1):1783-1787.
  24. Falkenburg JH, Jansen J, van der Vaart-Duinkerken N, et al. Polymorphic and monomorphic HLA-DR determinants on human hematopoietic progenitor cells. *Blood*. 1984;63(5):1125-1132.
  25. Orgad S, Yunis EJ, Zaizov R, Ramot B, Altshuler R, Gazit E. Expression of HLA-DR alloantigens on acute lymphoblastic leukemia lymphoblasts. *Hum Immunol*. 1984;9(2):67-74.
  26. Kobayashi KS, van den Elsen PJ. NLRC5: a key regulator of MHC class I-dependent immune responses. *Nature reviews Immunology*. 2012;12(12):813-820.
  27. Rutten CE, van Luxemburg-Heijs SA, Halkes CJ, et al. Patient HLA-DP-specific CD4+ T cells from HLA-DPB1-mismatched donor lymphocyte infusion can induce graft-versus-leukemia reactivity in the presence or absence of graft-versus-host disease. *Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation*. 2013;19(1):40-48.
  28. Herr W, Eichinger Y, Beshay J, et al. HLA-DPB1 mismatch alleles represent powerful leukemia rejection antigens in CD4 T-cell immunotherapy after allogeneic stem-cell transplantation. *Leukemia*. 2017;31(2):434-445.
  29. Stevanovic S, van Bergen CA, van Luxemburg-Heijs SA, et al. HLA class II upregulation during viral infection leads to HLA-DP-directed graft-versus-host disease after CD4+ donor lymphocyte infusion. *Blood*. 2013;122(11):1963-1973.
  30. Griffioen M, van Bergen CA, Falkenburg JH. Autosomal Minor Histocompatibility Antigens: How Genetic Variants

- Create Diversity in Immune Targets. *Frontiers in immunology*. 2016;7:100.
31. Pont MJ, Hobo W, Honders MW, et al. LB-ARHGDI1B-1R as a novel minor histocompatibility antigen for therapeutic application. *Haematologica*. 2015;100(10):e419-422.
  32. Norde WJ, Overes IM, Maas F, et al. Myeloid leukemic progenitor cells can be specifically targeted by minor histocompatibility antigen LRH-1-reactive cytotoxic T cells. *Blood*. 2009;113(10):2312-2323.
  33. Hobo W, Broen K, van der Velden WJ, et al. Association of disparities in known minor histocompatibility antigens with relapse-free survival and graft-versus-host disease after allogeneic stem cell transplantation. *Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation*. 2013;19(2):274-282.
  34. Meij P, Jedema I, van der Hoorn MA, et al. Generation and administration of HA-1-specific T-cell lines for the treatment of patients with relapsed leukemia after allogeneic stem cell transplantation: a pilot study. *Haematologica*. 2012;97(8):1205-1208.
  35. Marijt WA, Heemskerk MH, Kloosterboer FM, et al. Hematopoiesis-restricted minor histocompatibility antigens HA-1- or HA-2-specific T cells can induce complete remissions of relapsed leukemia. *Proc Natl Acad Sci U S A*. 2003;100(5):2742-2747.
  36. Griffioen M, van der Meijden ED, Slager EH, et al. Identification of phosphatidylinositol 4-kinase type II beta as HLA class II-restricted target in graft versus leukemia reactivity. *Proc Natl Acad Sci U S A*. 2008;105(10):3837-3842.
  37. Stumpf AN, van der Meijden ED, van Bergen CA, Willemze R, Falkenburg JH, Griffioen M. Identification of 4 new HLA-DR-restricted minor histocompatibility antigens as hematopoietic targets in antitumor immunity. *Blood*. 2009;114(17):3684-3692.
  38. Spaapen RM, Lokhorst HM, van den Oudenalder K, et al. Toward targeting B cell cancers with CD4+ CTLs: identification of a CD19-encoded minor histocompatibility antigen using a novel genome-wide analysis. *The Journal of experimental medicine*. 2008;205(12):2863-2872.
  39. Spaapen RM, de Kort RA, van den Oudenalder K, et al. Rapid identification of clinical relevant minor histocompatibility antigens via genome-wide zygosity-genotype correlation analysis. *Clin Cancer Res*. 2009;15(23):7137-7143.
  40. Meyer RG, Wagner EM, Konur A, et al. Donor CD4 T cells convert mixed to full donor T-cell chimerism and replenish the CD52-positive T-cell pool after alemtuzumab-based T-cell-depleted allo-transplantation. *Bone marrow transplantation*. 2010;45(4):668-674.
  41. Hughes AL, Yeager M. Natural selection and the evolutionary history of major histocompatibility complex loci. *Front Biosci*. 1998;3:d509-516.
  42. Morishima Y, Kashiwase K, Matsuo K, et al. Biological significance of HLA locus matching in unrelated donor bone marrow transplantation. *Blood*. 2015;125(7):1189-1197.
  43. Petersdorf EW, Gooley TA, Anasetti C, et al. Optimizing outcome after unrelated marrow transplantation by comprehensive matching of HLA class I and II alleles in the donor and recipient. *Blood*. 1998;92(10):3515-3520.
  44. Morishima Y, Sasazuki T, Inoko H, et al. The clinical significance of human leukocyte antigen (HLA) allele compatibility in patients receiving a marrow transplant from serologically HLA-A, HLA-B, and HLA-DR matched unrelated donors. *Blood*. 2002;99(11):4200-4206.
  45. Sasazuki T, Juji T, Morishima Y, et al. Effect of matching of class I HLA alleles on clinical outcome after

- transplantation of hematopoietic stem cells from an unrelated donor. Japan Marrow Donor Program. *The New England journal of medicine*. 1998;339(17):1177-1185.
46. Falkenburg JH, Jedema I. Allo-reactive T cells for the treatment of hematological malignancies. *Molecular oncology*. 2015;9(10):1894-1903.
  47. Sherman LA, Chattopadhyay S. The molecular basis of allorecognition. *Annu Rev Immunol*. 1993;11:385-402.
  48. Ford WL, Atkins RC. The proportion of lymphocytes capable of recognizing strong transplantation antigens in vivo. *Adv Exp Med Biol*. 1973;29(0):255-262.
  49. Ford WL, Simmonds SJ, Atkins RC. Early cellular events in a systemic graft-vs.-host reaction. II. Autoradiographic estimates of the frequency of donor lymphocytes which respond to each Ag-B-determined antigenic complex. *The Journal of experimental medicine*. 1975;141(3):681-696.
  50. Matzinger P, Bevan MJ. Hypothesis: why do so many lymphocytes respond to major histocompatibility antigens? *Cell Immunol*. 1977;29(1):1-5.
  51. Flomenberg N, Baxter-Lowe LA, Confer D, et al. Impact of HLA class I and class II high-resolution matching on outcomes of unrelated donor bone marrow transplantation: HLA-C mismatching is associated with a strong adverse effect on transplantation outcome. *Blood*. 2004;104(7):1923-1930.
  52. Woolfrey A, Klein JP, Haagenson M, et al. HLA-C antigen mismatch is associated with worse outcome in unrelated donor peripheral blood stem cell transplantation. *Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation*. 2011;17(6):885-892.
  53. Fernandez-Vina MA, Klein JP, Haagenson M, et al. Multiple mismatches at the low expression HLA loci DP, DQ, and DRB3/4/5 associate with adverse outcomes in hematopoietic stem cell transplantation. *Blood*. 2013;121(22):4603-4610.
  54. Edwards JA, Durant BM, Jones DB, Evans PR, Smith JL. Differential expression of HLA class II antigens in fetal human spleen: relationship of HLA-DP, DQ, and DR to immunoglobulin expression. *Journal of immunology*. 1986;137(2):490-497.
  55. Przepiorka D, Saliba R, Cleary K, et al. Tacrolimus does not abrogate the increased risk of acute graft-versus-host disease after unrelated-donor marrow transplantation with allelic mismatching at HLA-DRB1 and HLA-DQB1. *Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation*. 2000;6(2A):190-197.
  56. Petersdorf EW, Longton GM, Anasetti C, et al. Definition of HLA-DQ as a transplantation antigen. *Proc Natl Acad Sci U S A*. 1996;93(26):15358-15363.
  57. Shaw BE, Marsh SG, Mayor NP, Russell NH, Madrigal JA. HLA-DPB1 matching status has significant implications for recipients of unrelated donor stem cell transplants. *Blood*. 2006;107(3):1220-1226.
  58. Bettens F, Passweg J, Schanz U, et al. Impact of HLA-DPB1 haplotypes on outcome of 10/10 matched unrelated hematopoietic stem cell donor transplants depends on MHC-linked microsatellite polymorphisms. *Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation*. 2012;18(4):608-616.
  59. Ludajic K, Balavarca Y, Bickeboller H, et al. Impact of HLA-DPB1 allelic and single amino acid mismatches on HSCT. *British journal of haematology*. 2008;142(3):436-443.
  60. Shaw BE, Gooley TA, Malkki M, et al. The importance of HLA-DPB1 in unrelated donor hematopoietic cell transplantation. *Blood*. 2007;110(13):4560-4566.

61. Rutten CE, van Luxemburg-Heijs SA, Griffioen M, et al. HLA-DP as specific target for cellular immunotherapy in HLA class II-expressing B-cell leukemia. *Leukemia*. 2008;22(7):1387-1394.
62. Zino E, Frumento G, Markt S, et al. A T-cell epitope encoded by a subset of HLA-DPB1 alleles determines nonpermissive mismatches for hematologic stem cell transplantation. *Blood*. 2004;103(4):1417-1424.
63. Crivello P, Zito L, Sizzano F, et al. The impact of amino acid variability on alloreactivity defines a functional distance predictive of permissive HLA-DPB1 mismatches in hematopoietic stem cell transplantation. *Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation*. 2015;21(2):233-241.
64. Fleischhauer K, Shaw BE. HLA-DP in unrelated hematopoietic cell transplantation revisited: challenges and opportunities. *Blood*. 2017;130(9):1089-1096.
65. Crocchiolo R, Zino E, Vago L, et al. Nonpermissive HLA-DPB1 disparity is a significant independent risk factor for mortality after unrelated hematopoietic stem cell transplantation. *Blood*. 2009;114(7):1437-1444.
66. Fleischhauer K, Fernandez-Vina MA, Wang T, et al. Risk associations between HLA-DPB1 T-cell epitope matching and outcome of unrelated hematopoietic cell transplantation are independent of HLA-DPA1. *Bone marrow transplantation*. 2014;49(9):1176-1183.
67. Fleischhauer K, Shaw BE, Gooley T, et al. Effect of T-cell-epitope matching at HLA-DPB1 in recipients of unrelated-donor haemopoietic-cell transplantation: a retrospective study. *The Lancet Oncology*. 2012;13(4):366-374.
68. Arrieta-Bolanos E, Crivello P, Shaw BE, et al. In silico prediction of nonpermissive HLA-DPB1 mismatches in unrelated HCT by functional distance. *Blood Adv*. 2018;2(14):1773-1783.
69. Petersdorf EW, Malkki M, O'Huigin C, et al. High HLA-DP Expression and Graft-versus-Host Disease. *The New England journal of medicine*. 2015;373(7):599-609.
70. Crivello P, Heinold A, Rebmann V, et al. Functional distance between recipient and donor HLA-DPB1 determines nonpermissive mismatches in unrelated HCT. *Blood*. 2016;128(1):120-129.